نتایج جستجو برای: blinatumomab
تعداد نتایج: 330 فیلتر نتایج به سال:
Objective Pediatric patients with relapsed or refractory acute lymphoblastic leukemia have a poor prognosis. We here assess the response rates, adverse events, and long-term follow-up of pediatric relapsed/refractory receiving blinatumomab. Methods Retrospective analysis single-center experience blinatumomab in 38 over period 10 years. Results The median age at onset therapy was years (1-21 yea...
Multi-agent chemotherapy is the standard treatment for most B cell malignancies. Since chemotherapy can be associated with significant toxicity and since relapses resistant to chemotherapy often develop, new therapies are needed. Blinatumomab (AMG 103 or MT103) is a late-stage candidate in clinical development, which belongs to a novel class of antibody constructs termed bi-specific T cell enga...
ALL: acute lymphoblastic leukemia INTRODUCTION Blinatumomab is the first-in-class bispecific T-cell engager antibody approved for the treatment of refractory acute lymphoblastic leukemia (ALL). It simultaneously binds endogenous CD3 cytotoxic T cells and CD19 B cells, resulting in T-celle mediated serial lysis of normal and malignant B cells. Although studies have been conducted into the incide...
Blinatumomab has shown efficacy in B-cell malignancies. Rapid clearance of peripheral B cells has been demonstrated, resulting in sustained B-cell depletion throughout the treatment period. This report describes serum immunoglobulin levels during and after blinatumomab treatment in a phase 2 study in patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia (ALL)....
BiTE antibodies are novel recombinant single chain Ig domain constructs that leverage the endogenous cytotoxic potential of polyclonal T cells to target malignant cells by utilizing the specific binding properties of variable domains from two different antibodies. Antibody-based immunotherapy represents a promising strategy in cancer. BiTE antibodies have demonstrated efficacy in hematologic ma...
Bispecific T-cell Engagers (BiTE®) antibody constructs enable a polyclonal T-cell response to cell-surface tumor-associated antigens, bypassing the narrow specificities of T-cell receptors and the need for antigen presentation through the major histocompatibility complex pathways. Blinatumomab, a CD19xCD3 BiTE® antibody construct, received accelerated approval for the treatment of relapsed/refr...
In adults with acute lymphoblastic leukemia (ALL), advances in chemotherapy have improved hematologic response rates to greater than 80% and relapses rates to below 50%. Leukemic cells not detected by conventional morphological methods may persist or reappear after chemotherapy as minimal residual disease (MRD), defined as at least 10 (0.01%) leukemic cells detected by quantitative polymerase c...
Conventional treatment for cancer such as surgical resection and chemotherapy can cause damage in cases with advanced cancers. Moreover, the identification of tumor-specific targets has great importance in T-cell therapies. For decades, T cell activity has been stimulated to improve anti-tumor activity. Bispecific antibodies have attracted strong interest from pharmaceutical companies, for thei...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید